Collegium Pharmaceutical, Inc.
Symbol: COLL
NASDAQ
37.51
USDTržní cena dnes
25.1608
Poměr P/E
1.5484
Poměr PEG
1.20B
MRK Cap
- 0.00%
Výnos DIV
Collegium Pharmaceutical, Inc. (COLL) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1210.06 | 310.5 | 173.7 | 186.4 | |||||||||||
balance-sheet.row.short-term-investments | 159.35 | 71.6 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 707.98 | 179.5 | 183.1 | 105.8 | |||||||||||
balance-sheet.row.inventory | 125.38 | 32.3 | 46.5 | 17.4 | |||||||||||
balance-sheet.row.other-current-assets | 51.76 | 0.1 | 16.7 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 2110.28 | 537.6 | 420 | 315.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 94.93 | 22 | 26.4 | 27.1 | |||||||||||
balance-sheet.row.goodwill | 535.43 | 133.9 | 133.7 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1900.47 | 421.7 | 567.5 | 268.7 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2435.9 | 555.6 | 701.2 | 268.7 | |||||||||||
balance-sheet.row.long-term-investments | 3.52 | 1 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.tax-assets | 100.57 | 26.3 | 23.9 | 78 | |||||||||||
balance-sheet.row.other-non-current-assets | 3.89 | 0.8 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 2638.81 | 605.7 | 754.1 | 376.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.account-payables | 17.76 | 8.7 | 39.6 | 33.4 | |||||||||||
balance-sheet.row.short-term-debt | 737.3 | 184.3 | 163.6 | 49.2 | |||||||||||
balance-sheet.row.tax-payables | 21.59 | 7.1 | 4.4 | 3.2 | |||||||||||
balance-sheet.row.long-term-debt-total | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 1015.23 | 264.9 | 66.9 | 147.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 29.98 | 7.1 | 8.2 | 8.8 | |||||||||||
balance-sheet.row.total-liab | 3994.26 | 947.9 | 979.3 | 489.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -1082.85 | -233.2 | -281.3 | -256.3 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.08 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1837.62 | 428.6 | 476.1 | 459.2 | |||||||||||
balance-sheet.row.total-stockholders-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4749.1 | - | - | - | |||||||||||
Total Investments | 161.9 | 71.6 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.total-debt | 2961.26 | 674.3 | 872.8 | 258.8 | |||||||||||
balance-sheet.row.net-debt | 1910.56 | 435.3 | 699.1 | 72.3 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 48.16 | 48.2 | -25 | 71.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 149.26 | 149.3 | 138.9 | 68.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.15 | -2.2 | -8.4 | -78 | |||||||||||
cash-flows.row.stock-based-compensation | 27.14 | 27.1 | 22.9 | 24.3 | |||||||||||
cash-flows.row.change-in-working-capital | 21.73 | 21.7 | -12.7 | 13.5 | |||||||||||
cash-flows.row.account-receivables | 3.59 | 3.6 | -21.8 | -22.5 | |||||||||||
cash-flows.row.inventory | 14.17 | 14.2 | 48.3 | -2.3 | |||||||||||
cash-flows.row.account-payables | 5.06 | 5.1 | -0.7 | -5.8 | |||||||||||
cash-flows.row.other-working-capital | 23.77 | -1.1 | -38.5 | 44.1 | |||||||||||
cash-flows.row.other-non-cash-items | 30.62 | 30.6 | 8.5 | 3.4 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 274.75 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.acquisitions-net | -41.66 | 0 | -572.1 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -92.35 | -92.4 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 22 | 22 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 41.66 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -70.81 | -70.8 | -573.7 | -1.9 | |||||||||||
cash-flows.row.debt-repayment | -301.14 | -301.1 | -75 | -50 | |||||||||||
cash-flows.row.common-stock-issued | 1.84 | 9.1 | 11.8 | 12.7 | |||||||||||
cash-flows.row.common-stock-repurchased | -75.05 | -75 | -14.1 | -47.9 | |||||||||||
cash-flows.row.dividends-paid | -57.53 | -9.1 | 0 | -12.7 | |||||||||||
cash-flows.row.other-financing-activites | 291.69 | 236 | 514 | 8.6 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -140.18 | -140.2 | 436.7 | -89.3 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 63.76 | 63.8 | -12.7 | 12.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 1056.4 | 240 | 176.2 | 189 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 992.64 | 176.2 | 189 | 176.7 | |||||||||||
cash-flows.row.operating-cash-flow | 274.75 | 274.7 | 124.2 | 103.6 | |||||||||||
cash-flows.row.capital-expenditure | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.free-cash-flow | 274.29 | 274.3 | 122.6 | 101.6 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 566.77 | 566.8 | 463.9 | 276.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 240.6 | 240.6 | 254.4 | 126.3 | |||||||||||
income-statement-row.row.gross-profit | 326.17 | 326.2 | 209.5 | 150.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 159.21 | 159.2 | 176.2 | 128.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 399.81 | 399.8 | 430.6 | 254.7 | |||||||||||
income-statement-row.row.interest-income | 15.62 | 15.6 | 1 | 0 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 152 | 149.3 | 138.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-caps | 331.83 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 166.96 | 167 | -104.6 | -46.7 | |||||||||||
income-statement-row.row.income-before-tax | 75.73 | 75.7 | -28.8 | -3.4 | |||||||||||
income-statement-row.row.income-tax-expense | 27.58 | 27.6 | -3.8 | -74.9 | |||||||||||
income-statement-row.row.net-income | 48.16 | 48.2 | -25 | 71.5 |
Často kladené otázky
Co je Collegium Pharmaceutical, Inc. (COLL) celková aktiva?
Collegium Pharmaceutical, Inc. (COLL) celková aktiva jsou 1143308000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 286454000.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.575.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 8.492.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.085.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.295.
Co je Collegium Pharmaceutical, Inc. (COLL) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 48155000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 674283000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 159208000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 238947000.000.